Microarray to determine responsiveness of tumors to antiangiogenic treatment

Colorectal cancer (CRC) is the third most frequently occurring cancer in both sexes. It ranks second in developed countries. Tumor growth beyond the critical two to three millimeter diameter and metastasis require angiogenesis. Therefore, in later tumor stages, antiangiogenic treatment offers a strategy that has been shown in clinic to improve outcomes in patients with advanced or metastatic colorectal cancer (mCRC). Today, several antiangiogenic drugs for tumor therapeutic application have been approved, e.g. Bevacizumab (Avastin®), Cetuximab (Erbitux®) or Panitumumab (Vectibix®). Nevertheless, 20% of the patients do not respond and are resistant to antiangiogenic therapy.
This invention provides a method which allows to further improve the efficacy of antiangiogenic therapy in colorectal cancer (CRC). This is achieved by detection and exclusion of patients, which are in a therapy resistant tumor stage.

Further information: PDF

Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0

Contact
Peer Biskup

As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.